Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.83 |
| ▸ | GAK | O14976 | 3/20 | 0.83 |
| ▸ | FBP1 | P09467 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | MAPT | P10636 | 1/20 | 0.83 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.69 |
| ▸ | RET | P07949 | 3/20 | 0.69 |
| ▸ | KDR | P35968 | 3/20 | 0.69 |
| ▸ | ILK | Q13418 | 2/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.69 |
| ▸ | BUB1 | O43683 | 2/20 | 0.69 |
| ▸ | STK10 | O94804 | 2/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | LCK | P06239 | 2/20 | 0.69 |
| ▸ | LYN | P07948 | 2/20 | 0.69 |
| ▸ | SRC | P12931 | 2/20 | 0.69 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.69 |
| ▸ | FECH | P22830 | 2/20 | 0.69 |
| ▸ | FLT3 | P36888 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615083 | 1.00 | EGFR (0.83) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL28197803 | 0.99 | EGFR (0.82) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL667895 | 0.91 | EGFR (1.00) | EGFRGAKFBP1ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507455 | 0.90 | EGFR (0.98) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL14862082 | 0.89 | FBP1 (0.84) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL20127269 | 0.89 | EGFR (0.85) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL15946889 | 0.88 | EGFR (0.85) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL644810 | 0.87 | EGFR (0.83) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1507690 | 0.87 | EGFR (0.83) | EGFRGAKFBP1ALDH1A1MAPT | |
| SCHEMBL1507609 | 0.86 | EGFR (0.78) | EGFRGAKFBP1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114394942-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-113264888-A | Tyrosine kinase inhibitor and pharmaceutical application thereof | 江苏康可得生物技术股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-107674059-B | Benzaheteroaromatic ring compound and preparation method and application thereof | 中国药科大学 | 2020-04-14 | — | — | CN | disclosed |
| EP-2590966-B1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LTD (CN) | 2016-08-31 | — | — | EP | disclosed |
| US-9168253-B2 | Quinazoline compounds | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-10-27 | — | — | US | disclosed |
| US-9168253-B2 | Quinazoline compounds | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-10-27 | — | — | US | disclosed |
| EP-2318378-B1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2013-10-23 | — | — | EP | disclosed |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-08-22 | — | — | US | disclosed |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-08-22 | — | — | US | disclosed |
| US-20130172373-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-04 | — | — | US | disclosed |
| US-20130172373-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-04 | — | — | US | disclosed |
| US-8426430-B2 | Quinazoline derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-04-23 | — | — | US | disclosed |
| US-8426430-B2 | Quinazoline derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-04-23 | — | — | US | disclosed |
| WO-2012000356-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000182-A1 | QUINAZOLINE COMPOUNDS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-01-05 | — | — | WO | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172373-A1 | QUINAZOLINE COMPOUNDS | EGFR, ABL1, ERBB2 | EGFR 1/4885GAK 440/4885FBP1 2873/4885 |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | EGFR 1042/4885GAK 493/4885FBP1 3168/4885 |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | EGFR 1042/4885GAK 493/4885FBP1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.